NasdaqCM:PLSEMedical Equipment
Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot
Pulse Biosciences (PLSE) has placed its nPulse Cardiac Catheter Ablation System at the center of its plans, following European feasibility data in Atrial Fibrillation and upcoming pivotal studies and conference presentations.
See our latest analysis for Pulse Biosciences.
These AFib data and the new focus on the nPulse Cardiac Catheter program come after a strong run, with a 90 day share price return of 45.39% and a very large 3 year total shareholder return. At the same time, the 1 year...